Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,044 public trials 2,018 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Recruiting

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

NCT07003295

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Emory University Hospital Midtown Atlanta, Georgia, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • Emory Saint Joseph's Hospital Atlanta, Georgia, United States
View Trial Details
Recruiting

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

NCT05010005

Conditions
Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +22 more
Locations
  • University of Miami (Data Collection Only) Miami, Florida, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
View Trial Details
Recruiting

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

NCT04915248

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • A.O. Spedali Civili di Brescia - Ematologia Brescia, Italy
  • Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia Milan, Italy
  • U.O. Ematologia AO di Padova Padova, Italy
  • Ematologia IRCCS Policlinico S. Matteo di Pavia Pavia, Italy
View all 18 locations
View Trial Details
Recruiting

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

NCT07225439

Conditions
B-cell Non Hodgkin Lymphoma, Chronic Disease, Chronic Lymphocytic Leukemia, +30 more
Locations
  • Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center Cleveland, Ohio, United States
  • Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute Cleveland, Ohio, United States
View Trial Details
Recruiting

Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom

NCT05557695

Conditions
Chronic Lymphocytic Leukemia, CLL, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • Research Site Aylesbury, United Kingdom
  • Research Site Bath, United Kingdom
  • Research Site Birmingham, United Kingdom
  • Research Site Bournemouth, United Kingdom
View all 29 locations
View Trial Details
Recruiting

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

NCT06980480

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Infirmary Health - Diagnostic & Medical Clinic (DMC) Mobile, Alabama, United States
  • Chao Family Comprehensive Cancer Center UCI Orange, California, United States
  • University of Kansas Westwood, Kansas, United States
  • University of Maryland | Greenebaum Cancer Center Baltimore, Maryland, United States
View all 56 locations
View Trial Details
Recruiting

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

NCT06561360

Conditions
Hairy Cell Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Mayo Clinic Cancer Center Rochester, Minnesota, United States
  • Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
View Trial Details
Recruiting

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

NCT06854653

Conditions
CTCL, Disease Attributes, Hemic and Lymphatic Diseases, +15 more
Locations
  • City of Hope Comprehensive Cancer Cente Duarte, California, United States
  • University of California Irvine Irvine, California, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View all 15 locations
View Trial Details

Related conditions